Jochem Potenberg

2.0k total citations
32 papers, 324 citations indexed

About

Jochem Potenberg is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jochem Potenberg has authored 32 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 21 papers in Cancer Research and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jochem Potenberg's work include Breast Cancer Treatment Studies (16 papers), HER2/EGFR in Cancer Research (13 papers) and Cancer Treatment and Pharmacology (7 papers). Jochem Potenberg is often cited by papers focused on Breast Cancer Treatment Studies (16 papers), HER2/EGFR in Cancer Research (13 papers) and Cancer Treatment and Pharmacology (7 papers). Jochem Potenberg collaborates with scholars based in Germany, Italy and Switzerland. Jochem Potenberg's co-authors include Salah‐Eddin Al‐Batran, Nadia Harbeck, Ralf‐Dieter Hofheinz, Rachel Wuerstlein, H. Schulz, Andreas Schneeweiß, Ulrike Nitz, Deniz Gencer, Georg Bolz and Toralf Reimer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Jochem Potenberg

30 papers receiving 315 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jochem Potenberg Germany 11 229 156 99 46 41 32 324
N. Vardakis Greece 11 348 1.5× 113 0.7× 201 2.0× 9 0.2× 64 1.6× 35 436
Marie-Thérèse Closon Belgium 5 420 1.8× 180 1.2× 79 0.8× 70 1.5× 27 0.7× 8 454
Raffaella Longarini Italy 9 297 1.3× 113 0.7× 123 1.2× 36 0.8× 142 3.5× 16 409
R. K. Ramanathan United States 11 292 1.3× 45 0.3× 103 1.0× 32 0.7× 35 0.9× 32 370
Ji Hyun Park South Korea 8 123 0.5× 36 0.2× 146 1.5× 12 0.3× 60 1.5× 22 307
F. Daniel United Kingdom 8 232 1.0× 93 0.6× 174 1.8× 22 0.5× 144 3.5× 13 374
M. Karina Greece 8 180 0.8× 40 0.3× 119 1.2× 10 0.2× 63 1.5× 12 277
Won Jin Chang South Korea 12 177 0.8× 91 0.6× 110 1.1× 6 0.1× 30 0.7× 27 353
M.H. Galea United Kingdom 11 166 0.7× 218 1.4× 52 0.5× 140 3.0× 112 2.7× 22 443
S. Della Torre Italy 9 338 1.5× 96 0.6× 89 0.9× 39 0.8× 18 0.4× 22 414

Countries citing papers authored by Jochem Potenberg

Since Specialization
Citations

This map shows the geographic impact of Jochem Potenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jochem Potenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jochem Potenberg more than expected).

Fields of papers citing papers by Jochem Potenberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jochem Potenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jochem Potenberg. The network helps show where Jochem Potenberg may publish in the future.

Co-authorship network of co-authors of Jochem Potenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Jochem Potenberg. A scholar is included among the top collaborators of Jochem Potenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jochem Potenberg. Jochem Potenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gluz, Oleg, Ulrike Nitz, Matthias Christgen, et al.. (2023). Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast Cancer. JAMA Oncology. 9(7). 946–946. 16 indexed citations
2.
Harbeck, Nadia, Raquel von Schumann, Ronald Kates, et al.. (2021). Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. Cancers. 13(19). 4884–4884. 10 indexed citations
3.
Harbeck, Nadia, Oleg Gluz, Rachel Würstlein, et al.. (2021). The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials. The Breast. 59. 58–66. 6 indexed citations
4.
Gluz, Oleg, Ulrike Nitz, Matthias Christgen, et al.. (2021). Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial.. Journal of Clinical Oncology. 39(15_suppl). 504–504. 2 indexed citations
5.
6.
Al‐Batran, Salah‐Eddin, Alexander Reichart, Claudia Pauligk, et al.. (2021). Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.. Journal of Clinical Oncology. 39(3_suppl). 406–406. 22 indexed citations
7.
Harbeck, Nadia, Ulrike Nitz, Matthias Christgen, et al.. (2020). LBA14 De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab+ET in early HR+/HER2+ breast cancer (BC): ADAPT-TP survival results. Annals of Oncology. 31. S1146–S1146. 5 indexed citations
8.
9.
Hildebrandt, Guido, Angrit Stachs, Bernd Gerber, et al.. (2020). Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial. International Journal of Radiation Oncology*Biology*Physics. 107(4). 683–693. 19 indexed citations
10.
Gluz, Oleg, Ulrike Nitz, Matthias Christgen, et al.. (2020). De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+/HER2+ early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study.. Journal of Clinical Oncology. 38(15_suppl). 515–515. 10 indexed citations
11.
12.
Chekerov, Radoslav, Peter Klare, Petra Krabisch, et al.. (2017). Panitumumab in platinum-sensitive epithelial ovarian cancer patients with KRAS wild-type: The PROVE-study, a phase II randomized multicenter study of the North-Eastern German Society of Gynaecologic Oncology.. Journal of Clinical Oncology. 35(15_suppl). 5558–5558. 6 indexed citations
13.
14.
Hofheinz, Ralf‐Dieter, Deniz Gencer, H. Schulz, et al.. (2015). Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. Journal of Clinical Oncology. 33(22). 2444–2449. 55 indexed citations
15.
16.
Thuss‐Patience, Peter, Salah‐Eddin Al‐Batran, Jens T. Siveke, et al.. (2015). Pazopanib and 5-FU/oxaliplatin as first-line treatment in advanced gastric cancer: PaFLO, a randomized phase II study from the AIO (Arbeitsgemeinschaft Internistische Onkologie).. Journal of Clinical Oncology. 33(15_suppl). 4033–4033. 16 indexed citations
17.
Reimer, Toralf, Jochem Potenberg, Bettina Conrad, et al.. (2009). 0155 ICE study: Ibandronate with or without capecitabine in elderly patients with early breast cancer. The Breast. 18. S58–S58. 2 indexed citations
18.
Reimer, Toralf, Gϋnter von Minckwitz, Jochem Potenberg, et al.. (2009). 4016 Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplements. 7(2). 219–220. 3 indexed citations
19.
Reimer, Toralf, Ulrike Nitz, Jochem Potenberg, et al.. (2009). 4003 ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements. 7(2). 215–215. 3 indexed citations
20.
Potenberg, Jochem, et al.. (1988). Enhancement and inhibition of benzo[a]pyrene-induced SOS function in E. coli by synthetic antioxidants. Mutation Research Letters. 207(1). 7–11. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by N. Vardakis Breakdown of academic impact, for papers by Marie-Thérèse Closon Breakdown of academic impact, for papers by Raffaella Longarini Breakdown of academic impact, for papers by R. K. Ramanathan Breakdown of academic impact, for papers by Ji Hyun Park Breakdown of academic impact, for papers by F. Daniel Breakdown of academic impact, for papers by M. Karina Breakdown of academic impact, for papers by Won Jin Chang Breakdown of academic impact, for papers by M.H. Galea Breakdown of academic impact, for papers by S. Della Torre
Rankless by CCL
2026